Physician profile
Mark Chylinski
NPI 1710408539
$693.48
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.10 · 2022: $82.68 · 2023: $290 · 2024: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $120.49 | 2023-2024 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $101.70 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $97.66 | 2023-2024 | Wegovy |
| Biogen, INC. | $51.68 | 2021 | |
| Dynavax Technologies Corporation | $51.30 | 2024 | Heplisav-B |
| Lilly USA, LLC | $50.33 | 2022-2024 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $48.82 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $31.80 | 2022-2023 | Rexulti |
| Pfizer INC. | $31.73 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $25.51 | 2021 | |
| Glaxosmithkline, LLC. | $21.03 | 2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $16.52 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.35 | 2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $14.91 | 2021 | |
| Exact Sciences Corporation | $14.65 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chylinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.